Loading
Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays are designed to form a protective barrier within the nasal cavity, preventing viruses and allergens from attaching to the nasal epithelial tissue. Its current development pipeline features several targeted solutions, including PL-14, formulated to block nasal allergies; PL-15, aimed at combating COVID-19; and PL-16, for influenza prevention. Established in 2005, the company operates from its headquarters in Ra'anana, Israel.
Previous close
$11.24
−$1.32 · -10.51%
Regular session · ET · Market data may be delayed.
Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays are designed to form a protective barrier within the nasal cavity, preventing viruses and allergens from attaching to the nasal epithelial tissue. Its current development pipeline features several targeted solutions, including PL-14, formulated to block nasal allergies; PL-15, aimed at combating COVID-19; and PL-16, for influenza prevention. Established in 2005, the company operates from its headquarters in Ra'anana, Israel.
Day range
Current $11.24
52-week range
Current $11.24
Regular session · ET · Market data may be delayed.
AI-powered factor overview
GoAI Score
Hold
Wait — insufficient conviction to act
Valuation
40
Expensive
Sentiment
58
Mixed
Risk
50
Elevated Risk
Momentum
57
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays are designed to form a protective barrier within the nasal cavity, preventing viruses and allergens from attaching to the nasal epithelial tissue. Its current development pipeline features several targeted solutions, including PL-14, formulated to block nasal allergies; PL-15, aimed at combating COVID-19; and PL-16, for influenza prevention. Established in 2005, the company operates from its headquarters in Ra'anana, Israel.
Day range
Current $11.24
52-week range
Current $11.24
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | 342K USD | 118K USD | 4K USD | 5K USD | 6K USD |
| Gross profit | −342K USD | −118K USD | −4K USD | −5K USD | −6K USD |
| Research and development | 2.13M USD | 534K USD | 332K USD | 347K USD | 245K USD |
| Selling, general, and administrative | 3.77M USD | 768K USD | 303K USD | 548K USD | 452K USD |
| Operating expenses | 5.91M USD | 1.3M USD | 635K USD | 895K USD | 697K USD |
| Interest income | 370K USD | — | — | — | — |
| Interest expense | 3.14M USD | 3K USD | 2K USD | 2K USD | 2K USD |
| Depreciation and amortization | 342K USD | 118K USD | 4K USD | 5K USD | 6K USD |
| Operating income | −6.25M USD | −1.3M USD | −635K USD | −895K USD | −703K USD |
| Net income | −3.34M USD | −1.55M USD | −600K USD | −779K USD | −711K USD |
Company facts updated Sep 6, 2026.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
